<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.0 20120330//EN" "JATS-archivearticle1.dtd">
<article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" article-type="research-article"><?properties open_access?><front><journal-meta><journal-id journal-id-type="nlm-ta">J Ovarian Res</journal-id><journal-id journal-id-type="iso-abbrev">J Ovarian Res</journal-id><journal-title-group><journal-title>Journal of Ovarian Research</journal-title></journal-title-group><issn pub-type="epub">1757-2215</issn><publisher><publisher-name>BioMed Central</publisher-name><publisher-loc>London</publisher-loc></publisher></journal-meta><article-meta><article-id pub-id-type="pmid">27184139</article-id><article-id pub-id-type="pmc">4869387</article-id><article-id pub-id-type="publisher-id">237</article-id><article-id pub-id-type="doi">10.1186/s13048-016-0237-8</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research</subject></subj-group></article-categories><title-group><article-title>GnRH antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome: a randomized controlled trial</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name><surname>Fouda</surname><given-names>Usama M.</given-names></name><address><phone>+201095401375</phone><email>umfrfouda@yahoo.com</email></address><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Sayed</surname><given-names>Ahmed M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Elshaer</surname><given-names>Hesham S.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Hammad</surname><given-names>Bahaa Eldin M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Shaban</surname><given-names>Mona M.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Elsetohy</surname><given-names>Khaled A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><contrib contrib-type="author"><name><surname>Youssef</surname><given-names>Mohamed A.</given-names></name><xref ref-type="aff" rid="Aff1"/></contrib><aff id="Aff1">Department of Obstetrics and Gynecology, Faculty of Medicine, Cairo University, Kasr Al-Ainy Hospital, Al-Saraya Street, Cairo, Egypt </aff></contrib-group><pub-date pub-type="epub"><day>17</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="pmc-release"><day>17</day><month>5</month><year>2016</year></pub-date><pub-date pub-type="collection"><year>2016</year></pub-date><volume>9</volume><elocation-id>29</elocation-id><history><date date-type="received"><day>3</day><month>4</month><year>2016</year></date><date date-type="accepted"><day>27</day><month>4</month><year>2016</year></date></history><permissions><copyright-statement>&#x000a9; Fouda et al. 2016</copyright-statement><license license-type="OpenAccess"><license-p>
<bold>Open Access</bold>This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">http://creativecommons.org/licenses/by/4.0/</ext-link>), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (<ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/publicdomain/zero/1.0/">http://creativecommons.org/publicdomain/zero/1.0/</ext-link>) applies to the data made available in this article, unless otherwise stated.</license-p></license></permissions><abstract id="Abs1"><sec><title>Background</title><p>The aim of this study was to compare the efficacy of antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins) combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who were at high risk for OHSS.</p></sec><sec><title>Methods</title><p>Two hundred and thirty six patients were randomized in a 1:1 ratio to the cabergoline group or the antagonist rescue combined with cabergoline group. Both groups received oral cabergoline (0.5&#x000a0;mg/day) for eight days beginning on the day of HCG administration. In the antagonist rescue combined with cabergoline group, when the leading follicle reached 16&#x000a0;mm, GnRH agonist (triptorelin) was replaced with GnRH antagonist (cetrorelix acetate) and the dose of HP-uFSH was reduced to 75&#x000a0;IU/day. HCG (5,000&#x000a0;IU/I.M) was administered when the serum estradiol level dropped below 3500&#x000a0;pg/ml. The study was open label and the outcome assessors (laboratory staff and the doctor who performed oocyte retrieval) were blind to treatment allocation.</p></sec><sec><title>Results</title><p>The incidence of moderate/severe OHSS was significantly lower in the antagonist rescue combined with cabergoline group [5.08&#x000a0;% Vs 13.56&#x000a0;%, P value =0.025, OR&#x02009;=&#x02009;0.342, 95&#x000a0;% CI, 0.129&#x02013;0.906]. Four cycles were cancelled in the cabergoline group. There were no significant differences between the groups with respect to the number of retrieved oocytes, metaphase II oocytes, high quality embryos and fertilization rate. Moreover, the implantation and pregnancy rates were comparable between both groups.</p></sec><sec><title>Conclusion</title><p>GnRH antagonist rescue protocol combined with cabergoline is more effective than cabergoline alone in the prevention of OHSS.</p></sec><sec><title>Trial registration</title><p>Clinical trial.gov (<ext-link ext-link-type="uri" xlink:href="https://clinicaltrials.gov/ct2/show/results/NCT02461875">NCT02461875</ext-link>).</p></sec></abstract><kwd-group xml:lang="en"><title>Keywords</title><kwd>Cabergoline</kwd><kwd>IVF-ET</kwd><kwd>Ovarian hyperstimulation syndrome</kwd><kwd>GnRH antagonist</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>issue-copyright-statement</meta-name><meta-value>&#x000a9; The Author(s) 2016</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="Sec1" sec-type="introduction"><title>Background</title><p>Ovarian hyperstimulation syndrome (OHSS) is the most dangerous iatrogenic complication associated with ovarian stimulation. Cystic enlargement of the ovaries, increased capillary permeability and fluid shift from the intravascular space into the third space are the main characteristics of OHSS [<xref ref-type="bibr" rid="CR1">1</xref>].</p><p>Several strategies have been proposed to prevent or minimize the intensity of OHSS. Cycle cancellation, withholding gonadotropins administration and postponing human chorionic gonadotropin (HCG) injection till HCG drops to a safe level (coasting),antagonist rescue protocol, embryos freezing, minimal stimulation IVF, in vitro maturation of oocytes, metformin administration in patients with polycystic ovary syndrome, natural cycle IVF, triggering ovulation with a reduced dose of HCG or with GnRH agonist in GnRH antagonists stimulation cycle and administration of GnRH antagonist after oocyte retrieval have all been used. Apart from cycle cancelation, none of these strategies have been effective in the complete prevention of OHSS [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>].</p><p>The primary pathophysiological feature of OHSS is increased capillary permeability, which results in fluid shift to the third space. It appears that the main cause of increased capillary permeability is the release of vasoactive-angiogenic substances (interleukins, tumor necrosis factor (TNF) &#x003b1;, endothelin and vascular endothelial growth factor (VEGF)) from the ovaries in response to exogenous or endogenous HCG [<xref ref-type="bibr" rid="CR1">1</xref>, <xref ref-type="bibr" rid="CR2">2</xref>]. Moreover, several authors suggested that the circulating peripheral blood mononuclear cells may be involved in the pathophysiology of OHSS. In vitro studies, revealed that HCG stimulates the production of IL8 and VEGF by monocytes [<xref ref-type="bibr" rid="CR3">3</xref>]. Kosaka et al. [<xref ref-type="bibr" rid="CR4">4</xref>] observed that peripheral blood mononuclear cells of patients with OHSS produce excessive amounts of VEGF. Several studies have revealed that VEGF is the primary vasoactive-angiogenic substance responsible for the development of OHSS. VEGF stimulates neovascularization and increased capillary permeability by interacting with VEGF receptor 2 (VEGFR-2). Gonadotropins stimulate the expression of VEGF and VEGFR-2 mRNA in granulosa cells and HCG (exogenous or endogenous) accentuates this expression [<xref ref-type="bibr" rid="CR5">5</xref>, <xref ref-type="bibr" rid="CR6">6</xref>].</p><p>Recent animal and human studies have revealed that dopamine agonists antagonize VEGF dependent vascular permeability by inhibiting VEGFR-2 phosphorylation and signaling. The use of cabergoline (a dopamine receptor-2 agonist) in the prevention of OHSS has been investigated in several studies. Three meta-analyses have revealed that cabergoline reduces the incidence of moderate/severe OHSS without affecting implantation, pregnancy and miscarriage rates [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR6">6</xref>, <xref ref-type="bibr" rid="CR7">7</xref>].</p><p>Antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins) is another effective strategy for preventing OHSS. Several studies have shown that the antagonist rescue protocol causes a rapid reduction in the estradiol level, prevents cycle cancelation, and reduces the risk of moderate/severe OHSS [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>].</p><p>Recently, Rollene et al. [<xref ref-type="bibr" rid="CR10">10</xref>] reported the use of cabergoline and GnRH antagonist (ganirelix) in the outpatient treatment of four patients with OHSS. Cabergoline combined with ganirelix resulted in rapid resolution of the clinical symptoms of OHSS. None of the patients required hospitalization.</p><p>The aim of this study was to compare the efficacy of antagonist rescue protocol combined with cabergoline versus cabergoline alone in the prevention of ovarian hyperstimulation syndrome (OHSS) in patients pretreated with GnRH agonist long protocol who were at high risk for OHSS.</p></sec><sec id="Sec2" sec-type="materials|methods"><title>Methods</title><p>During the period between March 2013 and December 2015, this prospective, two arm, assessor blinded, randomized controlled trial was conducted at the assisted conception unit of Aljazeera (Al Gazeera) hospital, Giza, Egypt. The study protocol followed the CONSORT guidelines for reporting parallel group randomised trials [<xref ref-type="bibr" rid="CR11">11</xref>]. This study included 236 patients who were stimulated using the long luteal GnRH agonist protocol and at high risk for developing OHSS [have more than 20 follicles (90&#x000a0;% of them less than 14&#x000a0;mm in mean diameter) and serum estradiol&#x02009;&#x02265;&#x02009;3000&#x000a0;pg/ml] [<xref ref-type="bibr" rid="CR9">9</xref>]. The exclusion criteria were an age less than 18&#x000a0;years or more than 37&#x000a0;years, endometriosis, presence of submucous or intramural myoma of more than 5&#x000a0;cm, recurrent abortion and a previous IVF-ET cycle. Patients with lung fibrosis, swelling or inflammation around the heart or lung, hypertension, liver disease, heart valve disease, or an allergy to cabergoline or ergot derivatives were also excluded from the study. The ethics committee of the hospital approved the study protocol [N-2-2013] and the patients provided informed consent before randomization. The study was registered at clinical trials.gov [NCT02461875].</p><p>Patients were randomized to the cabergoline group and the antagonist rescue combined with cabergoline group using a computer generated randomization list (obtained from <ext-link ext-link-type="uri" xlink:href="http://graphpad.com/quickcalcs/randomN1.cfm">http://graphpad.com/quickcalcs/randomN1.cfm</ext-link>) and sequentially numbered sealed envelopes containing allocation information written on a card. The randomization list and sealed envelopes were prepared by a statistician who was not involved in the allocation process. The sequentially numbered envelopes were opened by the study nurse and the patients were informed of their assigned group. The laboratory staff and the doctor who performed oocyte retrieval (Fouda U.M) were blinded to the treatment received.</p><p>All patients recruited to this study were stimulated using the long luteal GnRH agonist protocol [<xref ref-type="bibr" rid="CR12">12</xref>]. Triptorelin (Decapeptyl, Ipsen, Slough, United Kingdom) at a daily dose of 0.1&#x000a0;mg/S.C was started one week before anticipated menstruation. In PCOS patients with oligomenorrhea or amenorrhea, medroxyprogesterone acetate tablets (Provera Pfizer, Inc., New York, NY) (5&#x000a0;mg twice daily) were administered orally for 5&#x000a0;days to induce withdrawal bleeding. Following withdrawal bleeding, the patients received a 3-week course of combined oral contraception pills (Gynera, Bayer-Shering, Pharma-AG, Germany) from day 2 of menstruation. Triptorelin (0.1&#x000a0;mg/day) was started from day 20 of the cycle. After confirmation of pituitary down regulation (serum E<sub>2</sub> levels less than 50&#x000a0;pg/ml and endometrial thickness less than 5&#x000a0;mm) highly purified urinary FSH(HP-uFSH) (Fostimon, IBSA, Switzerland) was administered. The starting gonadotropins dose was determined according to the age, antral follicle count, basal FSH and E<sub>2</sub> levels and body mass index. Follicular development was monitored by transvaginal ultrasonography and serum estradiol. The starting dose of gonadotropins was not adjusted during stimulation.</p><p>In cabergoline group, cabergoline (Dostinex; Pfizer, Italy) at a daily dose of 0.5&#x000a0;mg was administered orally at bed time for 8&#x000a0;days starting on the day of HCG administration. HCG (Pregnyl; N.V. Organon, Oss, Holland) at a dose of 5,000&#x000a0;IU/I.M was administered when three or more follicles&#x02009;&#x02265;&#x02009;18&#x000a0;mm in diameter were detected by ultrasound examination.</p><p>In antagonist rescue combined with cabergoline group, when the leading follicle reached 16&#x000a0;mm, HP-uFSH was continued at a daily dose of 75&#x000a0;IU until and including the day of HCG administration. Triptorelin was discontinued and GnRH antagonist (Cetrorelix acetate)(Cetrotide; Serono International S.A., Geneva, Switzerland) 0.25&#x000a0;mg/S.C was administered daily until and including the day of HCG administration. Serum estradiol was measured daily and HCG (5,000&#x000a0;IU/I.M) was administered when the serum estradiol level dropped below 3500&#x000a0;pg/ml. Moreover, cabergoline (0.5&#x000a0;mg/day) was administered orally at bed time for 8&#x000a0;days starting on the day of HCG administration.</p><p>Oocyte retrieval was performed under deep sedation 36&#x02009;&#x000b1;&#x02009;2&#x000a0;h after HCG administration. Two or three embryos were transferred 3&#x000a0;days after oocyte retrieval. Pregnancy test was performed two weeks after embryo transfer. Transvaginal ultrasound was performed five weeks after embryo transfer to detect the presence of intrauterine gestational sac.</p><p>The luteal phase was supported with progesterone vaginal pessaries (Prontogest, Marcyrl, Egypt) 400&#x000a0;mg twice daily, starting on the day of oocyte retrieval until 12&#x000a0;weeks gestation or negative B-subunit HCG. The occurrence and severity of OHSS was defined according to the classification described by Golan et al. [<xref ref-type="bibr" rid="CR13">13</xref>]. The detection of ascites by ultrasound examination in patients with features with mild OHSS (enlarged ovaries (5&#x02013;12&#x000a0;cm), abdominal discomfort, nausea, vomiting and diarrhea) indicated the occurrence of moderate OHSS. The presence of clinically evident ascites and/or hydrothorax, increased blood viscosity and coagulation abnormality indicated the occurrence of severe OHSS. Patients with severe OHSS were hospitalized. OHSS with an onset&#x02009;&#x02264;&#x02009;10&#x000a0;days from oocyte retrieval was defined as early onset OHSS and OHSS with later onset was defined as late onset OHSS.</p><p>Clinical and ultrasound examinations were performed on the day of embryo transfer and after 4, 8 and 14&#x000a0;days to detect the occurrence of OHSS. All patients were instructed to contact us if they experienced difficulty in breathing, decreased urine volume, dizziness on standing, abdominal pain, enlargement of the abdomen and rapid weight gain.</p><p>The primary outcome measure was the incidence of moderate/severe OHSS and the secondary outcome measures were the number of retrieved oocytes, metaphase II oocytes, fertilization rate, implantation rate, miscarriage rate, clinical pregnancy rate (presence of intrauterine gestational sac detected by transvaginal ultrasound), and ongoing pregnancy rate (pregnancies continued beyond 20&#x000a0;weeks).</p><sec id="Sec3"><title>Sample size calculation</title><p>At the time of study design, a Cochrane review revealed that the incidence of moderate or severe OHSS in patients at high risk of developing OHSS treated with cabergoline was 16.95&#x000a0;% [<xref ref-type="bibr" rid="CR2">2</xref>]. We considered that 11.95&#x000a0;% difference in the incidence of moderate/severe OHSS between the group of patients treated with cabergoline alone and the group of patients treated with the antagonist rescue protocol combined with cabergoline would be of clinical significance. To detect an 11.95&#x000a0;% difference in the incidence of moderate/severe OHSS between both groups, 107 patients would have to be recruited to each group of the study to achieve a study power of 80&#x000a0;% at a significance level of 0.05 (calculated on https//<ext-link ext-link-type="uri" xlink:href="http://www.sealedenvelope.com/power/continuous-superiority">www.sealedenvelope.com/power/continuous-superiority</ext-link>). We expected that the dropout incidence would be 10&#x000a0;%; therefore, 118 patients were recruited to each arm of the study.</p></sec><sec id="Sec4"><title>Statistical analysis</title><p>Statistical analysis was performed using student&#x02019;s t test and &#x003c7;2 test, as appropriate. Fisher&#x02019;s exact test was used when the expected frequency was less than 5. A probability value (<italic>P</italic> value) less than 0.05 was considered statistically significant. All statistical calculations were performed using Excel version 7 (Microsoft, New York, NY, USA) and SPSS (SPSS, Chicago, IL, USA). Absolute risk reduction (95&#x000a0;% CI) and number needed to treat (95&#x000a0;% CI) were calculated on <ext-link ext-link-type="uri" xlink:href="http://graphpad.com/quickcalcs/NNT1/">http://graphpad.com/quickcalcs/NNT1/</ext-link>. An intention to treat analysis and per protocol analysis were performed.</p></sec></sec><sec id="Sec5" sec-type="results"><title>Results</title><p>Between March 2013 and December 2015, 2458 IVF-ET cycles were performed in our institution. Among the 334 patients who were at high risk for OHSS, 88 patients did not meet the inclusion criteria and 10 patients declined to participate in the study. We enrolled 236 patients with 118 patients randomized to each arm of the study. The flow of the patients in the study is shown in Fig.&#x000a0;<xref rid="Fig1" ref-type="fig">1</xref>.<fig id="Fig1"><label>Fig. 1</label><caption><p>The flow of the patients in the study</p></caption><graphic xlink:href="13048_2016_237_Fig1_HTML" id="MO1"/></fig></p><p>There were no significant differences between both groups with respect to age, body mass index (BMI), duration of infertility, cause of infertility, antral follicle count and baseline hormonal profile (Table&#x000a0;<xref rid="Tab1" ref-type="table">1</xref>).<table-wrap id="Tab1"><label>Table 1</label><caption><p>Baseline characteristics of patients</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>Antagonist rescue combined with cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Age (years)</td><td>27.35&#x02009;&#x000b1;&#x02009;5.98</td><td>26.69&#x02009;&#x000b1;&#x02009;5.58</td><td>0.387</td></tr><tr><td>Body mass index (Kg/m<sup>2</sup>)</td><td>25.85&#x02009;&#x000b1;&#x02009;4.54</td><td>26.47&#x02009;&#x000b1;&#x02009;4.23</td><td>0.28</td></tr><tr><td>Duration of infertility (years)</td><td>5.76&#x02009;&#x000b1;&#x02009;2.65</td><td>6.14&#x02009;&#x000b1;&#x02009;2.58</td><td>0.275</td></tr><tr><td>Type of infertility</td><td/><td/><td/></tr><tr><td>&#x02022; Primary</td><td>102/118(86.44&#x000a0;%)</td><td>97/118(82.2&#x000a0;%)</td><td>0.371</td></tr><tr><td>&#x02022; Secondary</td><td>16/118(13.56&#x000a0;%)</td><td>21/118(17.8&#x000a0;%)</td><td>0.371</td></tr><tr><td>Basal FSH (IU/L)</td><td>6.29&#x02009;&#x000b1;&#x02009;1.53</td><td>6.31&#x02009;&#x000b1;&#x02009;1.48</td><td>0.897</td></tr><tr><td>Antral follicle count</td><td>21.46&#x02009;&#x000b1;&#x02009;4.17</td><td>22.05&#x02009;&#x000b1;&#x02009;3.75</td><td>0.252</td></tr><tr><td>Patients with amenorrhea or oligomenorrhea</td><td>12/118(10.17&#x000a0;%)</td><td>14/118(11.86&#x000a0;%)</td><td>0.678</td></tr><tr><td>Cause of infertility</td><td/><td/><td/></tr><tr><td>&#x02022; Tubal Factor</td><td>31/118(26.27&#x000a0;%)</td><td>40/118(33.9&#x000a0;%)</td><td>0.202</td></tr><tr><td>&#x02022; PCOS</td><td>32/118(27.12 %)</td><td>29/118(24.58 %)</td><td>0.656</td></tr><tr><td>&#x02022; Unexplained</td><td>17/118(14.41&#x000a0;%)</td><td>12/118(10.17&#x000a0;%)</td><td>0.322</td></tr><tr><td>&#x02022; Male Factor</td><td>20/118(16.95&#x000a0;%)</td><td>22/118(18.64&#x000a0;%)</td><td>0.734</td></tr><tr><td>&#x02022; Two or more factors</td><td>18/118(15.25&#x000a0;%)</td><td>15/118(12.71&#x000a0;%)</td><td>0.573</td></tr></tbody></table><table-wrap-foot><p>
<italic>PCOS</italic> polycystic ovary syndrome</p><p>Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD or n/n(%)</p></table-wrap-foot></table-wrap></p><p>The serum estradiol level on the day of HCG administration was significantly higher in the cabergoline group than in the antagonist rescue combined with cabergoline group (5501&#x02009;&#x000b1;&#x02009;1122 Vs. 2811&#x02009;&#x000b1;&#x02009;399&#x000a0;pg/ml, <italic>P</italic> value&#x02009;&#x0003c;&#x02009;0.001) (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).<table-wrap id="Tab2"><label>Table 2</label><caption><p>Outcome of ovarian stimulation</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>Antagonist rescue combined with cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Duration of HP-uFSH Stimulation (days)</td><td>9.92&#x02009;&#x000b1;&#x02009;0.85</td><td>10.08&#x02009;&#x000b1;&#x02009;0.68</td><td>0.129</td></tr><tr><td>Total HP-uFSH ampoules (75U)</td><td>29.88&#x02009;&#x000b1;&#x02009;6.8</td><td>27.87&#x02009;&#x000b1;&#x02009;5.58</td><td>0.014</td></tr><tr><td>Estradiol level on the HCG day (pg/ml)</td><td>5501&#x02009;&#x000b1;&#x02009;1122</td><td>2811&#x02009;&#x000b1;&#x02009;399</td><td>&#x0003c;0.001</td></tr><tr><td>No. of retrieved oocytes</td><td>19.09&#x02009;&#x000b1;&#x02009;4.01</td><td>18.85&#x02009;&#x000b1;&#x02009;4.37</td><td>0.651</td></tr><tr><td>No. of metaphase II oocytes</td><td>17.02&#x02009;&#x000b1;&#x02009;3.8</td><td>16.97&#x02009;&#x000b1;&#x02009;3.94</td><td>0.933</td></tr><tr><td>No. of fertilized oocytes</td><td>13.69&#x02009;&#x000b1;&#x02009;3.32</td><td>13.42&#x02009;&#x000b1;&#x02009;3.08</td><td>0.523</td></tr><tr><td>Fertilization rate</td><td>1584/2003(79.08&#x000a0;%)</td><td>1561/1940(80.46&#x000a0;%)</td><td>0.28</td></tr><tr><td>No. of high quality embryos</td><td>4.02&#x02009;&#x000b1;&#x02009;1.28</td><td>3.84&#x02009;&#x000b1;&#x02009;1.31</td><td>0.295</td></tr><tr><td>No. of embryos transferred</td><td>2.32&#x02009;&#x000b1;&#x02009;0.47</td><td>2.26&#x02009;&#x000b1;&#x02009;0.44</td><td>0.303</td></tr><tr><td>Cycles cancelled</td><td>4/118(3.39&#x000a0;%)</td><td>0/118(0&#x000a0;%)</td><td>0.122</td></tr><tr><td>Moderate or severe OHSS</td><td>16/118(13.56&#x000a0;%)</td><td>6/118(5.08&#x000a0;%)</td><td>0.025</td></tr><tr><td>Moderate OHSS</td><td>12/118(10.17&#x000a0;%)</td><td>6/118(5.08&#x000a0;%)</td><td>0.141</td></tr><tr><td>Severe OHSS</td><td>4/118(3.39&#x000a0;%)</td><td>0/118(0&#x000a0;%)</td><td>0.122</td></tr><tr><td>Early onset OHSS</td><td>12/118(10.17&#x000a0;%)</td><td>5/118(4.24&#x000a0;%)</td><td>0.078</td></tr><tr><td>Late onset OHSS</td><td>4/118(3.39&#x000a0;%)</td><td>1/118(0.85&#x000a0;%)</td><td>0.37</td></tr></tbody></table><table-wrap-foot><p>
<italic>OHSS</italic> ovarian hyperstimulation syndrome</p><p>Values are expressed as mean&#x02009;&#x000b1;&#x02009;SD or n/n(%)</p></table-wrap-foot></table-wrap></p><p>In the antagonist rescue combined with cabergoline group, the mean (SD) number of antagonist injections needed to reduce the estradiol level below 3500&#x000a0;pg/ml was 1.52(0.69). Seventy patients (59.32&#x000a0;%) required one GnRH antagonist dose, 35 patients (29.66 %) required two GnRH antagonist doses and 13 patients (11.02 %) required three GnRH antagonist doses to reduce the estradiol levels below 3500&#x000a0;pg/ml. The mean serum estradiol dropped by 34.56&#x000a0;% after the first 24&#x000a0;h of GnRH antagonist administration (5101 Vs. 3338&#x000a0;pg/ml). The drop in the serum estradiol level continued after the second and the third GnRH antagonist injections.</p><p>The incidence of moderate/severe OHSS was significantly lower in the antagonist rescue combined with cabergoline group [5.08&#x000a0;% Vs 13.56&#x000a0;%, <italic>P</italic> value =0.025, OR&#x02009;=&#x02009;0.342, 95&#x000a0;% CI,0.129&#x02013;0.906]. Absolute risk reduction was 8.48&#x000a0;% (95&#x000a0;% CI, 1.14&#x000a0;%&#x02013;15.81&#x000a0;%) and number needed to treat was 12 (95&#x000a0;% CI, 6.3&#x02013;88.1). Four patients in the cabergoline group had severe OHSS and none of the patients in the antagonist group had severe OHSS. Four cycles were cancelled in the cabergoline group and no cycles were cancelled in the antagonist rescue combined with cabergoline group (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>).</p><p>All patients in the antagonist rescue combined with cabergoline group received 75&#x000a0;IU/day of HP-uFSH when the leading follicle reached 16&#x000a0;mm and all patients in the cabergoline group received at least 150&#x000a0;IU/day of HP-uFSH during the stimulation period. The total gonadotropins dose administered till the leading follicle reached 16&#x000a0;mm was comparable between both groups [25.39 &#x000b1; 5.64 Vs. 24.32 &#x000b1; 6.62 ampules, P value = 0.184]. Conversely, the total gonadotropins dose administered after the leading follicle reached 16&#x000a0;mm was significantly lower in the antagonist rescue combined with cabergoline group (2.48&#x02009;&#x000b1;&#x02009;0.64 Vs. 5.56&#x02009;&#x000b1;&#x02009;1.92 ampules, <italic>P</italic> value&#x02009;&#x0003c;&#x02009;0.001).</p><p>There were no significant differences in the number of retrieved oocytes, metaphase II oocytes, fertilized oocytes, high quality embryos (grade 1 or 2) and fertilization rate between the two groups (Table&#x000a0;<xref rid="Tab2" ref-type="table">2</xref>). Moreover, the implantation rate and clinical and ongoing pregnancy rates were comparable between the two groups (Table&#x000a0;<xref rid="Tab3" ref-type="table">3</xref>). A case of ectopic pregnancy was reported in the antagonist rescue combined with cabergoline group.<table-wrap id="Tab3"><label>Table 3</label><caption><p>Reproductive outcomes</p></caption><table frame="hsides" rules="groups"><thead><tr><th/><th>Cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>Antagonist rescue combined with cabergoline group (<italic>n</italic>&#x02009;=&#x02009;118)</th><th>Odd ratio (95&#x000a0;% CI)</th><th>
<italic>P</italic> value</th></tr></thead><tbody><tr><td>Clinical pregnancy/started cycle</td><td>42/118(35.59&#x000a0;%)</td><td>46/118(38.98&#x000a0;%)</td><td>0.87[0.51&#x02013;1.47]</td><td char="." align="char">0.59</td></tr><tr><td>Clinical pregnancy/transfer cycle</td><td>42/114(36.84&#x000a0;%)</td><td>46/118(38.98&#x000a0;%)</td><td>0.91[0.54&#x02013;1.55]</td><td char="." align="char">0.74</td></tr><tr><td>Ongoing pregnancy/started cycle</td><td>37/118(31.36&#x000a0;%)</td><td>41/118(34.75&#x000a0;%)</td><td>0.86[0.5&#x02013;1.48]</td><td char="." align="char">0.578</td></tr><tr><td>Ongoing pregnancy/transfer cycle</td><td>37/114(32.46&#x000a0;%)</td><td>41/118(34.75&#x000a0;%)</td><td>0.9[0.52&#x02013;1.56]</td><td char="." align="char">0.708</td></tr><tr><td>Implantation rate</td><td>49/265(18.49&#x000a0;%)</td><td>53/267(19.85&#x000a0;%)</td><td>0.92[0.59&#x02013;1.41]</td><td char="." align="char">0.689</td></tr><tr><td>Multiple pregnancy rate</td><td>7/42(16.67&#x000a0;%)</td><td>6/46(13.04&#x000a0;%)</td><td>1.33[0.41&#x02013;4.34]</td><td char="." align="char">0.632</td></tr><tr><td>Spontaneous abortion rate</td><td>5/42(11.9&#x000a0;%)</td><td>5/46(10.87&#x000a0;%)</td><td>1.11[0.3&#x02013;4.14]</td><td char="." align="char">0.879</td></tr></tbody></table><table-wrap-foot><p>Values are expressed as n/n (%) unless otherwise indicated</p></table-wrap-foot></table-wrap></p></sec><sec id="Sec6" sec-type="discussion"><title>Discussion</title><p>The data presented in this study revealed that GnRH antagonist rescue protocol combined with cabergoline minimized the risk of moderate/severe OHSS and prevented cycle cancelation without affecting the number of oocytes retrieved, quality of embryos and implantation and pregnancy rates in patients at high risk for OHSS who were pretreated with GnRH agonist long protocol. To our knowledge, this is the first randomized controlled study that evaluated the role of antagonist rescue protocol combined with cabergoline in minimizing the risk of OHSS.</p><p>The presence of a large number of growing follicles and rapidly rising estradiol level are associated with an increased likelihood of developing OHSS. The causative role of estradiol in inducing OHSS has not been proved. It seems that patients with a large number of growing follicle have a large mass of granulosa cells that produce excessive amounts of estradiol and chemical mediators that are responsible for OHSS [<xref ref-type="bibr" rid="CR14">14</xref>]. Several authors have proposed several strategies, such as coasting and antagonist rescue protocol, to reduce estradiol levels in an effort to minimize the risk of OHSS [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>].</p><p>Coasting is one of the most commonly used preventive measures for OHSS. With this management strategy, gonadotropins administration is stopped, GnRH agonist administration is continued and HCG administration is delayed until estradiol drops to a safe level (&#x02264;3000&#x000a0;pg/ml). Withholding gonadotropins administration induces apoptosis of granulosa cells and therefore minimizes the production of estradiol and chemical mediators responsible for the development of OHSS [<xref ref-type="bibr" rid="CR15">15</xref>, <xref ref-type="bibr" rid="CR16">16</xref>]. Previous studies revealed that the duration of coasting is an important predictor of IVF outcomes. It seems that prolonged complete deprivation of gonadotropins (&#x0003e;3&#x000a0;days) is associated with a decrease in the number of oocytes retrieved, implantation rate and clinical pregnancy rate [<xref ref-type="bibr" rid="CR17">17</xref>, <xref ref-type="bibr" rid="CR18">18</xref>]. Antagonist rescue of agonist IVF cycles at risk of OHSS was first described by Gustafson et al. [<xref ref-type="bibr" rid="CR8">8</xref>]. In a retrospective study including 87 patients down-regulated with GnRH agonist who were at risk of OHSS, GnRH agonist was switched to GnRH antagonist in patients who failed to response to reducing the dose of gonadotropins. HCG was administered when the serum estradiol level fell to a safe level (&#x0003c;3000&#x000a0;pg/ml). Antagonist rescue resulted in a rapid decline in the serum estradiol levels without adverse effects on embryo quality, the fertilization rate or the pregnancy rates. The incidence of moderate/severe OHSS was 4.6&#x000a0;% [<xref ref-type="bibr" rid="CR8">8</xref>].</p><p>The exact mechanism by which GnRH antagonists induce a rapid decline in the estradiol level and reduce the risk of OHSS is not clear. Several studies have suggested that GnRH antagonists have a direct effect on the ovary mediated by interaction with the GnRH-I and GnRH-II receptors present on granulosa cells [<xref ref-type="bibr" rid="CR19">19</xref>, <xref ref-type="bibr" rid="CR20">20</xref>]. Asimakopoulos et al. [<xref ref-type="bibr" rid="CR21">21</xref>] reported that GnRH antagonists inhibit the production of VEGF from cultured human granulosa luteinized cells.</p><p>In a prospective randomized study, Aboulghar et al. [<xref ref-type="bibr" rid="CR9">9</xref>] compared coasting with antagonist rescue protocol in a series of 192 patients pretreated with GnRH agonist long protocol who were at high risk for OHSS. None of the patients in either groups experienced severe OHSS. The duration of coasting was significantly longer than the duration of antagonist administration (2.81&#x02009;&#x000b1;&#x02009;0.97 Vs. 1.74&#x02009;&#x000b1;&#x02009;0.91&#x000a0;days; <italic>P</italic>&#x02009;&#x0003c;&#x02009;0.001). Antagonist rescue protocol produced more high quality embryos and more oocytes. The rapid drop in the estradiol level with antagonist rescue protocol prevented prolonged deprivation of the growing follicles from gonadotropins which has a negative impact on the embryo quality and IVF-ET outcomes. Moreover, the administration of a low dose of gonadotropins (75 IU/day) in the antagonist rescue protocol group supported the function of granulosa cells and maintained the production of high quality embryos. Martinaz et al. [<xref ref-type="bibr" rid="CR22">22</xref>] replaced GnRH agonist with GnRH antagonist in the early stages of ovarian stimulation (after 6 to 8&#x000a0;days of gonadotropins administration) in a series of 19 patients who were at high risk for OHSS (more than 10 follicles per ovary and/or serum estradiol&#x02009;&#x0003e;&#x02009;900&#x000a0;pg/ml and the follicles expected to need 3 or more days to reach triggering criteria). The dose of gonadotropins was reduced and ovulation was triggered by rHCG in 14 patients and by a GnRH agonist bolus in 5 patients. The mean (SD) duration of antagonist administration was 4.8&#x02009;&#x000b1;&#x02009;0.8&#x000a0;days. No oocytes were retrieved in one patient triggered with a GnRH agonist bolus. One patient had moderate OHSS. The authors suggested that early administration of GnRH antagonist could allow triggering of ovulation with GnRH agonist bolus which is associated with a lower risk of OHSS compared to triggering ovulation with HCG. Further studies are needed to determine for how long pituitary desensitization and unresponsiveness to GnRH bolus trigger persist after switching GnRH agonist to GnRH antagonist.</p><p>In a retrospective study, Hill et al. [<xref ref-type="bibr" rid="CR23">23</xref>] replaced GnRH agonist with GnRH antagonist without reducing the dose of gonadotropins in 387 patients pretreated with microdose flare or long luteal agonist protocol who were at high risk of OHSS. In the majority of patients (98.45&#x000a0;%), one or two doses of GnRH antagonist were required to induced a rapid drop in the estradiol level. Antagonist rescue prevented cycle cancellation, as well as permitted continued gonadotropin administration and follicular development and maturation for an additional one to three days. The incidence of severe OHSS was 8&#x000a0;% and the cycle cancellation rate was 1.5&#x000a0;%.</p><p>The higher incidence of severe OHSS in the study by Hill et al. [<xref ref-type="bibr" rid="CR23">23</xref>] (8&#x000a0;%) in comparison with our study (0&#x000a0;%) and the studies of Aboulghar et al. [<xref ref-type="bibr" rid="CR9">9</xref>] (0&#x000a0;%), Martinez et al. [<xref ref-type="bibr" rid="CR22">22</xref>] (0&#x000a0;%) and Gustafson et al. [<xref ref-type="bibr" rid="CR8">8</xref>] (2.35&#x000a0;%) may be attributed to differences in the sample population or the treatment protocol. In the study by Hill et al. [<xref ref-type="bibr" rid="CR23">23</xref>], antagonist administration was not accompanied with adjustment in the dose of gonadotropins, whereas the dose of gonadotropins was reduced in other studies [<xref ref-type="bibr" rid="CR8">8</xref>, <xref ref-type="bibr" rid="CR9">9</xref>, <xref ref-type="bibr" rid="CR22">22</xref>]. Moreover, the duration of antagonist administration was longer in Martinaz et al. [<xref ref-type="bibr" rid="CR22">22</xref>] study in comparison with the study by Hill et al. [<xref ref-type="bibr" rid="CR23">23</xref>]. Further studies are needed to investigate the proper timing and duration of antagonist administration and the effect of reducing gonadotropins dose on the incidence of OHSS, the number of retrieved oocytes and the embryo quality.</p><p>Several studies revealed that the incidence of OHSS is lower in mild stimulation IVF cycles in comparison to conventional long agonist IVF cycles [<xref ref-type="bibr" rid="CR24">24</xref>, <xref ref-type="bibr" rid="CR25">25</xref>]. Reducing gonadotropins dose seems to be effective in minimizing the risk of OHSS. Large follicles have higher sensitivity to gonadotropins compared to medium and small sized follicles, and therefore with reducing the dose of gonadotropins, large follicles continue to grow and small and medium sized follicles become atretic. The atresia of medium and small sized follicles minimizes the production of chemical mediators responsible for development of OHSS [<xref ref-type="bibr" rid="CR26">26</xref>]. Moreover, reducing gonadotropins dose slows the rate of granulosa cells proliferation which produces the chemical mediators responsible for OHSS [<xref ref-type="bibr" rid="CR27">27</xref>].</p><p>Antagonist rescue protocol and cabergoline minimize the risk of OHSS by two different mechanisms. Antagonist rescue protocol inhibits estradiol and VEGF production by the growing follicles and cabergoline blocks VEGF mediated increased capillary permeability [<xref ref-type="bibr" rid="CR2">2</xref>, <xref ref-type="bibr" rid="CR21">21</xref>]. This means that cabergoline augments the effect antagonist rescue protocol.</p><p>In the current study, 5000&#x000a0;IU of HCG was used to trigger final oocyte maturation. The majority of studies revealed that the reproductive outcomes of IVF-ET cycles are comparable in women receiving 5000&#x000a0;IU or 10000&#x000a0;IU of HCG to trigger final oocyte maturation [<xref ref-type="bibr" rid="CR28">28</xref>]. Several authors suggested that the administration of 5000&#x000a0;IU of HCG instead of 10000&#x000a0;IU of HCG may minimize the risk of OHSS in patients who have a high risk for OHSS [<xref ref-type="bibr" rid="CR28">28</xref>, <xref ref-type="bibr" rid="CR29">29</xref>]. On the other hand, two small studies revealed that the administration of lower doses of HCG (&#x02264;5000 IU) does not reduce the incidence of OHSS in patients at high risk for OHSS [<xref ref-type="bibr" rid="CR30">30</xref>, <xref ref-type="bibr" rid="CR31">31</xref>].</p><p>In the current study, the administration of 5000&#x000a0;IU of HCG instead of 10000&#x000a0;IU of HCG to trigger final oocyte maturation may have an additive effect in minimizing the risk of OHSS in both groups. However, because the same dose of HCG (5000&#x000a0;IU) was used to trigger final oocyte maturation in both groups, we do not think that the administration of 5000&#x000a0;IU of HCG instead of 10000&#x000a0;IU of HCG is responsible for the greater efficacy of antagonist rescue protocol combined with cabergoline in minimizing the risk of OHSS in comparison to cabergoline alone.</p><p>The main strength of this study is the prospective randomized controlled design. Our study has two limitations. First, the patients and the doctors were not blind to the treatment allocation. Second, it is not clear whether antagonist administration, HP-uFSH dose reduction to 75&#x000a0;IU/day or the combination of both is responsible for minimizing the risk of OHSS. Further studies are needed to clarify this point.</p></sec><sec id="Sec7" sec-type="conclusion"><title>Conclusion</title><p>GnRH antagonist rescue protocol (replacing GnRH agonist with GnRH antagonist and reducing the dose of gonadotropins to 75&#x000a0;IU/day) combined with cabergoline is more effective than cabergoline alone in the prevention of OHSS in patients downregulated with GnRH agonist who are at high risk for OHSS.</p><sec id="Sec8"><title>Ethics approval and consent to participate</title><p>The ethics committee of Aljazeera (Al Gazeera) hospital approved the study protocol [N-2-2013] and the patients provided informed consent before randomization.</p></sec></sec></body><back><glossary><title>Abbreviations</title><def-list><def-item><term>BMI</term><def><p>body mass index</p></def></def-item><def-item><term>FSH</term><def><p>follicle stimulating hormone</p></def></def-item><def-item><term>GnRH</term><def><p>gonadotropin releasing hormone</p></def></def-item><def-item><term>HCG</term><def><p>human chorionic gonadotropin</p></def></def-item><def-item><term>HP-uFSH</term><def><p>highly purified urinary follicle stimulating hormone</p></def></def-item><def-item><term>IVF-ET</term><def><p>in vitro fertilization embryo transfer</p></def></def-item><def-item><term>OHSS</term><def><p>ovarian hyperstimulation syndrome</p></def></def-item><def-item><term>PCOS</term><def><p>polycystic ovary syndrome</p></def></def-item><def-item><term>rHCG</term><def><p>recombinant human chorionic gonadotropins</p></def></def-item><def-item><term>TNF</term><def><p>tumor necrosis factor</p></def></def-item><def-item><term>VEGF</term><def><p>vascular endothelial growth factor</p></def></def-item></def-list></glossary><fn-group><fn><p><bold>Competing interests</bold></p><p>The authors declare that they have no competing interests.</p></fn><fn><p><bold>Authors&#x02019; contributions</bold></p><p>All of the authors have made substantial contributions to conception and design, data collection, or data analysis and were involved in drafting the manuscript or revising it critically for important intellectual content. All authors have read and approved the final manuscript.</p></fn><fn><p><bold>Authors&#x02019; information</bold></p><p>Usama M. Fouda, Ahmed M. Sayed, Hesham S. Elshaer, Bahaa Eldin M. Hammad, Mona M. Shaban, Khaled A. Elsetohy, Mohamed A. Youssef. All the authors are from the Department of Obstetrics and Gynecology, Faculty of medicine, Cairo University, Cairo, Egypt.</p></fn></fn-group><ack><title>Acknowledgements</title><p>There are no acknowledgements.</p><sec id="FPar1"><title>Funding</title><p>No funding sources.</p></sec></ack><ref-list id="Bib1"><title>References</title><ref id="CR1"><label>1.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kumar</surname><given-names>P</given-names></name><name><surname>Sait</surname><given-names>SF</given-names></name><name><surname>Sharma</surname><given-names>A</given-names></name><name><surname>Kumar</surname><given-names>M</given-names></name></person-group><article-title>Ovarian hyperstimulation syndrome</article-title><source>J Hum Reprod Sci.</source><year>2011</year><volume>4</volume><fpage>70</fpage><lpage>5</lpage><pub-id pub-id-type="doi">10.4103/0974-1208.86080</pub-id><pub-id pub-id-type="pmid">22065820</pub-id></element-citation></ref><ref id="CR2"><label>2.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tang</surname><given-names>H</given-names></name><name><surname>Hunter</surname><given-names>T</given-names></name><name><surname>Hu</surname><given-names>Y</given-names></name><name><surname>Zhai</surname><given-names>SD</given-names></name><name><surname>Sheng</surname><given-names>X</given-names></name><name><surname>Hart</surname><given-names>RJ</given-names></name></person-group><article-title>Cabergoline for preventing ovarian hyperstimulation syndrome</article-title><source>Cochrane Database Syst Rev.</source><year>2012</year><volume>15</volume><fpage>CD008605</fpage><pub-id pub-id-type="pmid">22336848</pub-id></element-citation></ref><ref id="CR3"><label>3.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Tatsumi</surname><given-names>K</given-names></name><name><surname>Yoshioka</surname><given-names>S</given-names></name><name><surname>Sato</surname><given-names>Y</given-names></name><name><surname>Egawa</surname><given-names>H</given-names></name><etal/></person-group><article-title>Human chorionic gonadotropin (HCG) activates monocytes to produce IL-8 via a different pathway from luteinizing hormone (LH)/HCG receptor system</article-title><source>J Clin Endocrinol Metab</source><year>2002</year><volume>87</volume><fpage>5199</fpage><lpage>208</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-020341</pub-id><pub-id pub-id-type="pmid">12414893</pub-id></element-citation></ref><ref id="CR4"><label>4.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kosaka</surname><given-names>K</given-names></name><name><surname>Fujiwara</surname><given-names>H</given-names></name><name><surname>Yoshioka</surname><given-names>S</given-names></name><name><surname>Fujii</surname><given-names>S</given-names></name></person-group><article-title>Vascular endothelial growth factor production by circulating immune cells is elevated in ovarian hyperstimulation syndrome</article-title><source>Hum Reprod.</source><year>2007</year><volume>22</volume><fpage>1647</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1093/humrep/dem042</pub-id><pub-id pub-id-type="pmid">17356124</pub-id></element-citation></ref><ref id="CR5"><label>5.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Busso</surname><given-names>CE</given-names></name><name><surname>Garcia-Velasco</surname><given-names>J</given-names></name><name><surname>Gomez</surname><given-names>R</given-names></name><name><surname>Alvarez</surname><given-names>C</given-names></name><name><surname>Sim&#x000f3;n</surname><given-names>C</given-names></name><name><surname>Pellicer</surname><given-names>A</given-names></name></person-group><article-title>Symposium: update on prediction and management of OHSS. Prevention of OHSS--dopamine agonists</article-title><source>Reprod Biomed Online</source><year>2009</year><volume>19</volume><fpage>43</fpage><lpage>51</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60044-2</pub-id><pub-id pub-id-type="pmid">19573289</pub-id></element-citation></ref><ref id="CR6"><label>6.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leitao</surname><given-names>VM</given-names></name><name><surname>Moroni</surname><given-names>RM</given-names></name><name><surname>Seko</surname><given-names>LM</given-names></name><name><surname>Nastri</surname><given-names>CO</given-names></name><name><surname>Martins</surname><given-names>WP</given-names></name></person-group><article-title>Cabergoline for the prevention of ovarian hyperstimulation syndrome: systematic review and meta-analysis of randomized controlled trials</article-title><source>Fertil Steril.</source><year>2014</year><volume>101</volume><fpage>664</fpage><lpage>75</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2013.11.005</pub-id><pub-id pub-id-type="pmid">24360566</pub-id></element-citation></ref><ref id="CR7"><label>7.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Baumgarten</surname><given-names>M</given-names></name><name><surname>Polanski</surname><given-names>L</given-names></name><name><surname>Campbell</surname><given-names>B</given-names></name><name><surname>Raine-Fenning</surname><given-names>N</given-names></name></person-group><article-title>Do dopamine agonists prevent or reduce the severity of ovarian hyperstimulation syndrome in women undergoing assisted reproduction? A systematic review and meta-analysis</article-title><source>Hum Fertil (Camb)</source><year>2013</year><volume>16</volume><fpage>168</fpage><lpage>74</lpage><pub-id pub-id-type="doi">10.3109/14647273.2013.833348</pub-id><pub-id pub-id-type="pmid">24047196</pub-id></element-citation></ref><ref id="CR8"><label>8.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gustofson</surname><given-names>RL</given-names></name><name><surname>Segars</surname><given-names>JH</given-names></name><name><surname>Larsen</surname><given-names>FW</given-names></name></person-group><article-title>Ganirelix acetate causes a rapid reduction in estradiol levels without adversely affecting oocyte maturation in women pretreated with leuprolide acetate who are at risk of ovarian hyperstimulation syndrome</article-title><source>Hum Reprod</source><year>2006</year><volume>21</volume><fpage>2830</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1093/humrep/del059</pub-id><pub-id pub-id-type="pmid">16966348</pub-id></element-citation></ref><ref id="CR9"><label>9.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Aboulghar</surname><given-names>MA</given-names></name><name><surname>Mansour</surname><given-names>RT</given-names></name><name><surname>Amin</surname><given-names>YM</given-names></name><name><surname>Al-Inany</surname><given-names>HG</given-names></name><name><surname>Aboulghar</surname><given-names>MM</given-names></name><name><surname>Serour</surname><given-names>GI</given-names></name></person-group><article-title>A prospective randomized study comparing coasting with GnRH antagonist administration in patients at risk for severe OHSS</article-title><source>Reprod Biomed Online.</source><year>2007</year><volume>15</volume><fpage>271</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60339-2</pub-id><pub-id pub-id-type="pmid">17854523</pub-id></element-citation></ref><ref id="CR10"><label>10.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rollene</surname><given-names>NL</given-names></name><name><surname>Amols</surname><given-names>MH</given-names></name><name><surname>Hudson</surname><given-names>SB</given-names></name><name><surname>Coddington</surname><given-names>CC</given-names></name></person-group><article-title>Treatment of ovarian hyperstimulation syndrome using a dopamine agonist and gonadotropin releasing hormone antagonist: a case series</article-title><source>Fertil Steril</source><year>2009</year><volume>92</volume><fpage>1169.e15</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2009.05.062</pub-id><pub-id pub-id-type="pmid">19608177</pub-id></element-citation></ref><ref id="CR11"><label>11.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Moher</surname><given-names>D</given-names></name><name><surname>Schulz</surname><given-names>KF</given-names></name><name><surname>Altman</surname><given-names>DG</given-names></name></person-group><article-title>The CONSORT statement: revised recommendations for improving the quality of reports of parallel group randomized trials</article-title><source>Ann Intern Med.</source><year>2001</year><volume>134</volume><fpage>657</fpage><lpage>62</lpage><pub-id pub-id-type="doi">10.7326/0003-4819-134-8-200104170-00011</pub-id><pub-id pub-id-type="pmid">11304106</pub-id></element-citation></ref><ref id="CR12"><label>12.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fouda</surname><given-names>UM</given-names></name><name><surname>Sayed</surname><given-names>AM</given-names></name><name><surname>Abdelmoty</surname><given-names>HI</given-names></name><name><surname>Elsetohy</surname><given-names>KA</given-names></name></person-group><article-title>Ultrasound guided aspiration of hydrosalpinx fluid versus salpingectomy in the management of patients with ultrasound visible hydrosalpinx undergoing IVF-ET: a randomized controlled trial</article-title><source>BMC Womens Health.</source><year>2015</year><volume>15</volume><fpage>177</fpage><pub-id pub-id-type="doi">10.1186/s12905-015-0177-2</pub-id></element-citation></ref><ref id="CR13"><label>13.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Golan</surname><given-names>A</given-names></name><name><surname>Ron-el</surname><given-names>R</given-names></name><name><surname>Herman</surname><given-names>A</given-names></name><name><surname>Soffer</surname><given-names>Y</given-names></name><name><surname>Weinraub</surname><given-names>Z</given-names></name><name><surname>Caspi</surname><given-names>E</given-names></name></person-group><article-title>Ovarian hyperstimulation syndrome: an update review</article-title><source>Obstet. Gynecol. Surv.</source><year>1989</year><volume>44</volume><fpage>430</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1097/00006254-198906000-00004</pub-id><pub-id pub-id-type="pmid">2660037</pub-id></element-citation></ref><ref id="CR14"><label>14.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Agrawal</surname><given-names>R</given-names></name><name><surname>Tan</surname><given-names>SL</given-names></name><name><surname>Wild</surname><given-names>S</given-names></name><name><surname>Sladkevicius</surname><given-names>P</given-names></name><name><surname>Engnrann</surname><given-names>L</given-names></name><name><surname>Payne</surname><given-names>N</given-names></name><etal/></person-group><article-title>Serum vascular endothelium growth factor concentrations in in vitro fertilization cycles predict the risk of ovarian hyperstimulation syndrome</article-title><source>Fertil Steril</source><year>1999</year><volume>71</volume><fpage>287</fpage><lpage>93</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(98)00447-6</pub-id><pub-id pub-id-type="pmid">9988400</pub-id></element-citation></ref><ref id="CR15"><label>15.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>D&#x02019;Angelo</surname><given-names>A</given-names></name><name><surname>Brown</surname><given-names>J</given-names></name><name><surname>Amso</surname><given-names>NN</given-names></name></person-group><article-title>Coasting (withholding gonadotrophins) for preventing ovarian hyperstimulation syndrome</article-title><source>Cochrane Database Syst Rev.</source><year>2011</year><volume>15</volume><fpage>CD002811</fpage></element-citation></ref><ref id="CR16"><label>16.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>G</given-names></name><name><surname>Salem</surname><given-names>R</given-names></name><name><surname>Feinman</surname><given-names>M</given-names></name><name><surname>Dodge</surname><given-names>S</given-names></name><name><surname>Zouves</surname><given-names>C</given-names></name><name><surname>Knutzen</surname><given-names>V</given-names></name></person-group><article-title>Eliminating the risk of life-endangering complications following overstimulation with menotropin fertility agents: a report on women undergoing in vitro fertilization and embryo transfer</article-title><source>Obstet Gynecol.</source><year>1993</year><volume>81</volume><fpage>1009</fpage><lpage>11</lpage><pub-id pub-id-type="pmid">8497341</pub-id></element-citation></ref><ref id="CR17"><label>17.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mansour</surname><given-names>R</given-names></name><name><surname>Aboulghar</surname><given-names>M</given-names></name><name><surname>Serour</surname><given-names>G</given-names></name><name><surname>Amin</surname><given-names>Y</given-names></name><name><surname>Abou-Setta</surname><given-names>AM</given-names></name></person-group><article-title>Criteria of a successful coasting protocol for the prevention of severe ovarian hyperstimulation syndrome</article-title><source>Hum Reprod.</source><year>2005</year><volume>20</volume><fpage>3167</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1093/humrep/dei180</pub-id><pub-id pub-id-type="pmid">16006465</pub-id></element-citation></ref><ref id="CR18"><label>18.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nardo</surname><given-names>LG</given-names></name><name><surname>Cheema</surname><given-names>P</given-names></name><name><surname>Gelbaya</surname><given-names>TA</given-names></name><name><surname>Horne</surname><given-names>G</given-names></name><name><surname>Fitzgerald</surname><given-names>CT</given-names></name><name><surname>Pease</surname><given-names>EH</given-names></name><etal/></person-group><article-title>The optimal length of &#x02018;coasting protocol&#x02019; in women at risk of ovarian hyperstimulation syndrome undergoing in vitro fertilization</article-title><source>Hum Fertil (Camb)</source><year>2006</year><volume>9</volume><fpage>175</fpage><lpage>80</lpage><pub-id pub-id-type="doi">10.1080/14647270600787575</pub-id><pub-id pub-id-type="pmid">17008270</pub-id></element-citation></ref><ref id="CR19"><label>19.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Leung</surname><given-names>PC</given-names></name><name><surname>Cheng</surname><given-names>CK</given-names></name><name><surname>Zhu</surname><given-names>XM</given-names></name></person-group><article-title>Multi-factorial role of GnRH-I and GnRH-II in the human ovary</article-title><source>Mol Cell Endocrinol.</source><year>2003</year><volume>202</volume><fpage>145</fpage><lpage>53</lpage><pub-id pub-id-type="doi">10.1016/S0303-7207(03)00076-5</pub-id><pub-id pub-id-type="pmid">12770744</pub-id></element-citation></ref><ref id="CR20"><label>20.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Khosravi</surname><given-names>S</given-names></name><name><surname>Leung</surname><given-names>PC</given-names></name></person-group><article-title>Differential regulation of gonadotropin releasing hormone (GnRH)I and GnRHII messenger ribonucleic acid by gonadal steroids in human granulosa luteal cells</article-title><source>J Clin Endocrinol Metab.</source><year>2003</year><volume>88</volume><fpage>663</fpage><lpage>72</lpage><pub-id pub-id-type="doi">10.1210/jc.2002-020866</pub-id><pub-id pub-id-type="pmid">12574197</pub-id></element-citation></ref><ref id="CR21"><label>21.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Asimakopoulos</surname><given-names>B</given-names></name><name><surname>Nikolettos</surname><given-names>N</given-names></name><name><surname>Nehls</surname><given-names>B</given-names></name><name><surname>Diedrich</surname><given-names>K</given-names></name><name><surname>Al-Hasani</surname><given-names>S</given-names></name><name><surname>Metzen</surname><given-names>E</given-names></name></person-group><article-title>Gonadotropin-releasing hormone antagonists do not influence the secretion of steroid hormones but affect the secretion of vascular endothelial growth factor from human granulosa luteinized cell cultures</article-title><source>Fertil Steril</source><year>2006</year><volume>86</volume><fpage>636</fpage><lpage>41</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.01.046</pub-id><pub-id pub-id-type="pmid">16904114</pub-id></element-citation></ref><ref id="CR22"><label>22.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mart&#x000ed;nez</surname><given-names>F</given-names></name><name><surname>Mancini</surname><given-names>F</given-names></name><name><surname>Sol&#x000e9;</surname><given-names>M</given-names></name><name><surname>Jos&#x000e9; Gomez</surname><given-names>M</given-names></name><name><surname>Beatriz Rodr&#x000ed;guez</surname><given-names>D</given-names></name><name><surname>Buxaderas</surname><given-names>R</given-names></name><etal/></person-group><article-title>Antagonist rescue of agonist IVF cycle at risk of OHSS: a case series</article-title><source>Gynecol Endocrinol.</source><year>2014</year><volume>30</volume><fpage>145</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.3109/09513590.2013.860128</pub-id><pub-id pub-id-type="pmid">24266696</pub-id></element-citation></ref><ref id="CR23"><label>23.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hill</surname><given-names>MJ</given-names></name><name><surname>Chason</surname><given-names>RJ</given-names></name><name><surname>Payson</surname><given-names>MD</given-names></name><name><surname>Segars</surname><given-names>JH</given-names></name><name><surname>Csokmay</surname><given-names>JM</given-names></name></person-group><article-title>GnRH antagonist rescue in high responders at risk for OHSS results in excellent assisted reproduction outcomes</article-title><source>Reprod Biomed Online.</source><year>2012</year><volume>25</volume><fpage>284</fpage><lpage>91</lpage><pub-id pub-id-type="doi">10.1016/j.rbmo.2012.05.004</pub-id><pub-id pub-id-type="pmid">22796230</pub-id></element-citation></ref><ref id="CR24"><label>24.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hejinen</surname><given-names>EMEW</given-names></name><name><surname>Eijkemans</surname><given-names>MJC</given-names></name><name><surname>De Klerk</surname><given-names>C</given-names></name><name><surname>Polinder</surname><given-names>S</given-names></name><name><surname>Beckers</surname><given-names>NGM</given-names></name><name><surname>Klinkert</surname><given-names>ER</given-names></name><etal/></person-group><article-title>A mild treatment strategy for in vitro fertilization: a randomised non inferiority trial</article-title><source>Lancet</source><year>2007</year><volume>369</volume><fpage>743</fpage><lpage>9</lpage><pub-id pub-id-type="doi">10.1016/S0140-6736(07)60360-2</pub-id><pub-id pub-id-type="pmid">17336650</pub-id></element-citation></ref><ref id="CR25"><label>25.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Karimzadeh</surname><given-names>MA</given-names></name><name><surname>Ahmadi</surname><given-names>S</given-names></name><name><surname>Oskouian</surname><given-names>H</given-names></name><name><surname>Rahmani</surname><given-names>E</given-names></name></person-group><article-title>Comparison of mild stimulation and conventional stimulation in ART outcome</article-title><source>Arch Gynecol Obstet</source><year>2010</year><volume>281</volume><fpage>741</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1007/s00404-009-1252-4</pub-id><pub-id pub-id-type="pmid">19834718</pub-id></element-citation></ref><ref id="CR26"><label>26.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Sher</surname><given-names>G</given-names></name><name><surname>Zouves</surname><given-names>C</given-names></name><name><surname>Feinman</surname><given-names>M</given-names></name><name><surname>Maassarani</surname><given-names>G</given-names></name></person-group><article-title>&#x0201c;Prolonged coasting&#x0201d;: an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilization</article-title><source>Human Reproduction</source><year>1995</year><volume>10</volume><fpage>3107</fpage><lpage>9</lpage><pub-id pub-id-type="pmid">8822423</pub-id></element-citation></ref><ref id="CR27"><label>27.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Fluker</surname><given-names>MR</given-names></name><name><surname>Hooper</surname><given-names>WM</given-names></name><name><surname>Yuzpe</surname><given-names>A</given-names></name></person-group><article-title>Withholding gonadotropins (&#x0201c;coasting&#x0201d;) to minimize the risk of ovarian hyperstimulation during superovulation and in vitro fertilization-embryo transfer cycles</article-title><source>Fertil Steril</source><year>1999</year><volume>71</volume><fpage>294</fpage><lpage>301</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(98)00438-5</pub-id><pub-id pub-id-type="pmid">9988401</pub-id></element-citation></ref><ref id="CR28"><label>28.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tsoumpou</surname><given-names>I</given-names></name><name><surname>Muglu</surname><given-names>J</given-names></name><name><surname>Gelbaya</surname><given-names>TA</given-names></name><name><surname>Nardo</surname><given-names>LG</given-names></name></person-group><article-title>Symposium: update on prediction and management of OHSS. Optimal dose of HCG for final oocyte maturation in IVF cycles: absence of evidence?</article-title><source>Reprod Biomed Online</source><year>2009</year><volume>19</volume><issue>1</issue><fpage>52</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/S1472-6483(10)60045-4</pub-id><pub-id pub-id-type="pmid">19573290</pub-id></element-citation></ref><ref id="CR29"><label>29.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Whelan</surname><given-names>JG</given-names><suffix>3rd</suffix></name><name><surname>Vlahos</surname><given-names>NF</given-names></name></person-group><article-title>The ovarian hyperstimulation syndrome</article-title><source>Fertil Steril</source><year>2000</year><volume>73</volume><fpage>883</fpage><lpage>96</lpage><pub-id pub-id-type="doi">10.1016/S0015-0282(00)00491-X</pub-id><pub-id pub-id-type="pmid">10785212</pub-id></element-citation></ref><ref id="CR30"><label>30.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Schmidt</surname><given-names>DW</given-names></name><name><surname>Maier</surname><given-names>DB</given-names></name><name><surname>Nulsen</surname><given-names>JC</given-names></name><name><surname>Benadiva</surname><given-names>CA</given-names></name></person-group><article-title>Reducing the dose of human chorionic gonadotropin in high responders does not affect the outcomes of in vitro fertilization</article-title><source>Fertil Steril</source><year>2004</year><volume>82</volume><fpage>841</fpage><lpage>6</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2004.03.055</pub-id><pub-id pub-id-type="pmid">15482757</pub-id></element-citation></ref><ref id="CR31"><label>31.</label><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kolibianakis</surname><given-names>EM</given-names></name><name><surname>Papanikolaou</surname><given-names>EG</given-names></name><name><surname>Tournaye</surname><given-names>H</given-names></name><name><surname>Camus</surname><given-names>M</given-names></name><name><surname>Van Steirteghem</surname><given-names>AC</given-names></name><name><surname>Devroey</surname><given-names>P</given-names></name></person-group><article-title>Triggering final oocyte maturation using different doses of human chorionic gonadotrophin: a randomized pilot study in patients with polycystic ovary syndrome treated with gonadotropin-releasing hormone antagonists and recombinant follicle-stimulating hormone</article-title><source>Fertil Steril</source><year>2007</year><volume>88</volume><fpage>1382</fpage><lpage>8</lpage><pub-id pub-id-type="doi">10.1016/j.fertnstert.2006.12.058</pub-id><pub-id pub-id-type="pmid">17445806</pub-id></element-citation></ref></ref-list></back></article>